Literature DB >> 9724256

Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans.

A B Gorelick1, S S Koshy, F G Hooper, T C Bennett, W D Chey, W L Hasler.   

Abstract

Tricyclic antidepressants treat chronic pain both in patients with somatic illness and with functional bowel disorders. We compared the effects of amitriptyline on perception of cutaneous and gastrointestinal stimulation to assess differential analgesic effects of tricyclics on somatic and visceral pain. Cutaneous electrical stimulation and rectal and esophageal distension were performed before and after 21 days of double-blind 50 mg amitriptyline vs. placebo in healthy volunteers. Amitriptyline increased currents that elicited cutaneous threshold, moderate discomfort, and moderate pain compared with basal (P < 0.05), whereas placebo had no effect. Amitriptyline had no effect on perception of rectal and esophageal distension and did not alter luminal compliance; thus the lack of effect on perception is not due to altered visceral elastic wall properties. In conclusion, amitriptyline reduces perception of cutaneous stimulation but does not alter visceral perception or compliance. This investigation demonstrates differential effects of tricyclics on somatic and visceral afferent function in healthy humans and provides insight into mechanisms of action in chronic pain both from somatic disease and from functional bowel disorders.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9724256     DOI: 10.1152/ajpgi.1998.275.3.G460

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  29 in total

1.  Long-term outcome from tricyclic antidepressant treatment of functional chest pain.

Authors:  C Prakash; R E Clouse
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

Review 2.  Centrally acting agents and visceral sensitivity.

Authors:  J Fioramonti; L Bueno
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 3.  Pharmacology of serotonin: what a clinician should know.

Authors:  F De Ponti
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

Review 4.  Gastroparesis: current diagnostic challenges and management considerations.

Authors:  Shamaila Waseem; Baharak Moshiree; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

Review 5.  Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.

Authors:  Michael Camilleri; Lin Chang
Journal:  Gastroenterology       Date:  2008-10-09       Impact factor: 22.682

6.  Effects of amitriptyline on gastric sensorimotor function and postprandial symptoms in healthy individuals: a randomized, double-blind, placebo-controlled trial.

Authors:  Ernest P Bouras; Nicholas J Talley; Michael Camilleri; Duane D Burton; Michael G Heckman; Julia E Crook; Elliott Richelson
Journal:  Am J Gastroenterol       Date:  2008-08       Impact factor: 10.864

Review 7.  New therapies for functional bowel diseases.

Authors:  B Coulie; M Camilleri
Journal:  Curr Gastroenterol Rep       Date:  2000-10

8.  Treatment of Functional GI Disorders With Psychotropic Medicines: A Review of Evidence With a Practical Approach.

Authors:  Syed I M Thiwan; Douglas A Drossman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-09

Review 9.  Management of refractory typical GERD symptoms.

Authors:  Emidio Scarpellini; Daphne Ang; Ans Pauwels; Adriano De Santis; Tim Vanuytsel; Jan Tack
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-14       Impact factor: 46.802

Review 10.  Current perspectives on the diagnosis and treatment of functional esophageal disorders.

Authors:  Roy Dekel; Ronnie Fass
Journal:  Curr Gastroenterol Rep       Date:  2003-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.